Tumor Pathology Committee of Chinese Anti-Cancer Association, Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical Oncology
Zhonghua zhong liu za zhi [Chinese journal of oncology] 2021 Oct 23Human epidermal growth factor receptor 2 (HER-2) plays an important role in carcinogenesis and development of urothelial carcinoma. Overexpression of HER-2 is associated with poor prognosis of urothelial carcinoma. Although there is no significant benefit from anti-HER-2 targeted therapies of monoclonal antibody and tyrosine kinase inhibitor, Anti-HER-2 antibody-drug conjugate (HER-2-ADC) has shown a promising efficacy in urothelial carcinoma patients with HER-2 overexpression. Therefore, effectively screening the potential beneficiaries of HER-2-ADC drugs has become a new challenge. However, standardized HER-2 scoring system for urothelial carcinoma has yet to be developed. Thus, the Committees organized experts to reach this expert consensus based on the clinical practice of HER-2 expression, gene amplification and mutation testing in urothelial carcinoma, combined with the current research progress and internal discussion of committee members, in order to construct HER-2 testing standard of urothelial carcinoma and improve the accuracy of interpretation, to guide the clinical application.
Tumor Pathology Committee of Chinese Anti-Cancer Association, Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical Oncology. Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2021 Oct 23;43(10):1001-1006
PMID: 34695889
View Full Text